Patent · US Active

Excision of retroviral nucleic acid sequences

US12122997B2 · kind B2 · utility

0Cited by

0References

11Claims

0Family size

Assignee

Temple University-Of The Commonwealth System of Higher Education · US

Inventors

Kamel Khalili · Yeadon, US
Wenhui Hu · 流花街道, CN

Key dates

Filing date	Feb 13, 2017
Grant date	Oct 22, 2024
Priority date	—
Expiry date	Feb 12, 2038

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2750/14143
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Compositions for the in vivo delivery of a gene editing CRISPR/Cas9 complex was developed to eliminate integrated retroviral DNA sequences from latently infected human cells and animal disease models.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.